galleon pharmaceuticals

Our initial class of drugs works through the carotid body to improve rate, rhythm and respiratory output.

Newsroom

2-Sep-2014 ANESTHESIOLOGY – Opioid users breathe easier with novel drug to treat respiratory depression
2-Sep-2014 Galleon Pharmaceuticals Announces Publication of Proof-of-Concept Clinical Studies for GAL-021, Projected Use for the Emerging Perioperative Sleep Apnea Epidemic
9-May-2014 Philadelphia Business Journal – Sleep apnea pill nears human tests
7-May-2014 Philadelphia Business Journal – Would you rather wear a contraption or take a pill for sleep apnea?
22-Apr-2014 BioWorld Today – No snooze button: Galleon advances drug therapy for sleep apnea
8-Jan-2014 Galleon Scientists Win Prestigious Research Awards for First-in-Class Treatment of Emerging Perioperative Sleep Apnea Epidemic
11-Apr-2013 Galleon Pharmaceuticals Demonstrates Successful Clinical Proof-of-Concept for Lead Product from Sleep Apnea Drug-Discovery Platform
20-Sep-2012 Galleon Pharmaceuticals Reports Positive Results from Second Phase I Study of GAL-021 for Treatment of Respiratory Depression
7-May-2012 Galleon Pharmaceuticals Reports Positive Results from Phase I Study of GAL-021 For Treatment of Respiratory Depression
1-Dec-2011 Galleon Pharmaceuticals Names Lynne Brookes Senior Vice President and Chief Business Officer
  • Scientific Publiation 01: Lorem ipsum dolor sit amet, typicus refero, erat nisl vulpes.
  • Scientific Publiation 01: Lorem ipsum dolor sit amet, typicus refero, erat nisl vulpes.
  • Scientific Publiation 01: Lorem ipsum dolor sit amet, typicus refero, erat nisl vulpes.
  • Scientific Publiation 01: Lorem ipsum dolor sit amet, typicus refero, erat nisl vulpes.
  • Scientific Publiation 01: Lorem ipsum dolor sit amet, typicus refero, erat nisl vulpes.
  • Scientific Publiation 01: Lorem ipsum dolor sit amet, typicus refero, erat nisl vulpes.